Valuation: Seres Therapeutics, Inc.

Market Cap 47.16M 40.79M 38.1M 34.95M 65.73M 4.49B 66.77M 447M 175M 2.25B 177M 173M 7.44B P/E 2026 *
-1.12x
P/E 2027 * -0.74x
Enterprise Value 47.16M 40.79M 38.1M 34.95M 65.73M 4.49B 66.77M 447M 175M 2.25B 177M 173M 7.44B EV / Sales 2026 *
65.9x
EV / Sales 2027 * 132x
Free-Float
88.52%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Seres Therapeutics, Inc.

1 day+1.04%
1 week+0.83%
Current month+0.83%
1 month-40.17%
3 months-36.92%
6 months-65.11%
Current year-67.27%
1 week 4.7
Extreme 4.7
5.65
1 month 4.59
Extreme 4.59
7.45
Current year 4.59
Extreme 4.59
16.42
1 year 4.59
Extreme 4.59
29.98
3 years 4.59
Extreme 4.59
84.6
5 years 4.59
Extreme 4.59
233.8
10 years 4.59
Extreme 4.59
770
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2026
Chief Executive Officer 58 31/07/2025
President 51 01/03/2026
Director TitleAgeSince
Chairman 70 01/03/2026
Director/Board Member 50 14/01/2019
Director/Board Member 80 31/03/2015
Date Insider Type Main position Quantity % Market Cap.
08/07/26 Free

General Counsel

7,500 0.0774%
08/07/26 Free

Director

6,500 0.0671%
08/07/26 Free

Director

6,500 0.0671%
Change 5-day change 1-year change 3-year change Capi.($)
+1.04%+0.83%-68.15%-94.72% 47.16M
+8.49%+20.55%+69.74%+109.30% 68.12B
+1.25%+2.44%+32.55%+72.63% 55.18B
-1.09%+32.96%+19.95%+499.45% 28.63B
+2.72%+3.41%-15.88%-4.90% 23.53B
+10.83%+18.38%+52.76%+4.58% 23.99B
+6.50%+7.56%+38.20%-21.33% 18.45B
-3.88%+16.98%+199.30%+354.30% 15.83B
+6.20%+11.51%+34.94%+681.88% 16.44B
+3.58%+1.96%+44.61%+167.01% 13.4B
Average +3.56%+10.60%+40.80%+176.82% 26.36B
Weighted average by Cap. +4.36%+13.09%+49.46%+168.44%

Financials

2026 *2027 *
Net sales 716K 619K 578K 531K 998K 68.14M 1.01M 6.79M 2.66M 34.15M 2.69M 2.63M 113M 358K 310K 289K 265K 499K 34.07M 507K 3.39M 1.33M 17.08M 1.34M 1.31M 56.46M
Net income -44.6M -38.58M -36.03M -33.05M -62.16M -4.24B -63.15M -423M -166M -2.13B -167M -164M -7.03B -84.57M -73.16M -68.32M -62.67M -118M -8.05B -120M -802M -315M -4.03B -318M -311M -13.34B
Net Debt - -
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
07/08/26 US$4.870 +1.04% 62,321
06/08/26 US$4.820 -3.70% 80,162
05/08/26 US$5.005 -4.67% 141,747
04/08/26 US$5.250 +4.37% 40,457
03/08/26 US$5.030 +4.14% 29,845
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.870USD
Average target price
17.00USD
Spread / Average Target
+249.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MCRB Stock